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background: New-generation drug-eluting stents (DES) such as the Resolute® zotarolimus-eluting stent (R-ZES) have been shown to be safe and 
effective in the treatment of coronary artery disease. Long-term follow-up is necessary for clinicians to understand the risk to benefit ratio of these 
devices years after implantation.
Methods: The RESOLUTE US study enrolled 1,402 patients (1,561 lesions). Patients were treated with R-ZES for de novo native coronary lesions in 
1 or 2 vessels with lesion length ≤27 mm, reference vessel diameter (RVD) of 2.25-4.0 mm, and diameter stenosis ≥50% and <100%. Postprocedure 
dual antiplatelet therapy (DAPT) was planned for 6 months. The primary endpoint was target lesion failure (TLF; cardiac death, target vessel 
myocardial infarction, or clinically-driven target lesion revascularization). Follow-up is planned through 5 years.
results: The mean age of enrolled patients was 64.1 ± 10.7 years, 68% (n=X/1402) were male, 34% (n=482/1402) had diabetes, and 10% 
(n=X/1402) received dual-vessel treatment. Follow-up was 96% (n=1341) at 3 years. DAPT use was 56.9% at 3 years (n=X/X) TLF was 8.5% 
(n=X/1341) at 3 years. Academic Research Consortium definite or probable stent thrombosis was 0.3% (n=4/1341), with 2 events occurring 
between years 1 and 3. In patients with diabetes, TLF was 10.8% (50/465), and there were no stent thrombosis events. Outcomes through 4 years of 
follow-up will be presented at the 2013 American College of Cardiology Scientific Sessions.
conclusions: The 4-year outcomes of the RESOLUTE US study will provide clinicians with further valuable information on the long-term safety and 
efficacy of R-ZES.
